Suzhou Zelgen Biopharmaceuticals Co Ltd

The National Medical Products Administration will advance the implementation of the pharmaceutical trial data protection system, establish market exclusivity periods for pediatric drugs and rare disease medications, and strengthen pre-guidance for innovative drugs with new targets and mechanisms. A responsible official from the NMPA stated that it will also expand the "Spring Rain Action" for transforming clinical innovations in medical devices, and formulate clinical trial and review guiding principles in frontier areas such as brain-computer interfaces. Zhongtai Securities noted that AI4S is expanding from single-point tool applications to coordinated development across data, models, wet-lab experiments, and R&D processes, and that life science upstream and CXO companies with high-quality data accumulation, automated experimental platforms, and industrial customer bases are expected to benefit continuously. As of 11:22 on September 21, 2026, the Penghua STAR Market Healthcare ETF rose 3.87%, with constituent stock HitGen up 14.54%, and Zelgen Biopharmaceuticals and Huiyu Pharmaceutical following the gains; the Penghua Hang Seng Biotech ETF rose 4.56%.

Zelgen Pharmaceuticals Executive Vice President and Chief Scientific Officer Lyu Binhua revealed that the company has entered into a strategic partnership with multinational pharmaceutical company AbbVie regarding overseas licensing of its products. Lyu made the remarks while appearing on the first episode of the third season of the program "Hardcore Players in the Shanghai Market," themed "Innovative Drugs Crossing the Value Inflection Point." In 2025, Zelgen Pharmaceuticals reported revenue of 810 million yuan, up 52 percent year on year. In the first half of 2026, the company's revenue reached 1.205 billion yuan, achieving its first-ever half-year profit.

Zelgen Biopharma announced on the evening of September 6 that its marketing application for a new indication of injectable human thyrotropin beta, trademarked Zesuning, has been accepted by the National Medical Products Administration. The indication is for use after surgery in patients with differentiated thyroid cancer without distant metastasis, to assist radioactive iodine in clearing residual thyroid tissue.

Zelgen Pharmaceuticals released its 2026 interim report, with net profit attributable to the parent company reaching 640 million yuan. During the reporting period, total operating revenue was 1.205 billion yuan, and net cash flow from operating activities was 809 million yuan. The company's latest asset-liability ratio stands at 51.21%, gross margin at 94.64%, down 2.37 percentage points from the previous quarter, ROE at 37.20%, and diluted earnings per share at 2.42 yuan. In addition, total asset turnover was 0.37 times, inventory turnover was 0.35 times, the number of shareholders was 13,700, and the top ten shareholders held 42.50% of the total share capital.

The 2026 second-quarter reports of public funds show that well-known fund managers including Zhang Kun, Liu Yanchun, and Zhu Shaoxing collectively reduced their positions in core consumer assets such as baijiu during the second quarter, shifting their allocation focus toward the tech growth sector. In the top ten holdings of the E Fund Blue Chip Select managed by Zhang Kun, SMIC and Dongshan Precision were included for the first time. The concentration of holdings dropped from 90.5% at the end of the first quarter to 50.9%, and the overall position fell from 93% to 75%. The number of shares held in Wuliangye and Shanxi Xinghuacun Fenjiu declined by 70.68% and 70.91% respectively. The top ten holdings of the Invesco Great Wall Dingyi Mixed Fund managed by Liu Yanchun were completely replaced, with new additions including Konfoong Materials International and Zhongji Innolight. From the appointment of an additional manager on May 9 to June 30, the net value rose by 26.51%. The top ten holdings of the Fullgoal Tianhui Selected Growth Fund managed by Zhu Shaoxing underwent significant changes, with Zhongji Innolight and Zelgen Biopharmaceuticals entering for the first time. Kweichow Moutai dropped out of the top ten after being a major holding for 25 consecutive quarters, while the position in Sinocera was substantially reduced by 69.11%.